Ikarian Capital’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.44M Sell
1,933,000
-500,000
-21% -$1.86M 0.65% 39
2026
Q2
$11.4M Buy
+2,433,000
New +$8.32M 1.22% 22
2021
Q3
– Sell
-17,600
Closed -$666K – 225
2021
Q2
$666K Sell
17,600
-93,900
-84% -$3.36M 0.05% 175
2021
Q1
$4.12M Sell
111,500
-40,000
-26% -$1.59M 0.14% 135
2020
Q4
$5.02M Buy
+151,500
New +$4.39M 0.22% 95

Other funds holding CCCC

Ikarian Capital's CCCC Position: Q3 2026 in Review

Ikarian Capital reduced its C4 Therapeutics (CCCC) stake by 21% in Q3 2026, selling an estimated $1.86M and leaving 1,933,000 shares worth $6.44M. The position accounts for 0.65% of the portfolio, ranked #39.

Ikarian Capital first reported a position in CCCC in Q4 2020 and has held it in 5 quarters since. The position peaked at $11.4M in Q2 2026. 146 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Ikarian Capital held 1,933,000 shares of C4 Therapeutics worth $6.44M as of Q3 2026.
  • Ikarian Capital sold 500,000 C4 Therapeutics shares in Q3 2026, an estimated $1.86M.
  • C4 Therapeutics made up 0.65% of Ikarian Capital's portfolio in Q3 2026, its #39 holding.
  • Ikarian Capital first reported a position in C4 Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Ikarian Capital's C4 Therapeutics position peaked at $11.4M in Q2 2026.
  • 146 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Ikarian Capital's 13F filing for Q3 2026, filed 16 Nov 2026.